远程医疗平台Hims & Hers Health Inc.（HIMS）今日夜盘股价大涨5.02%，引起了市场的广泛关注。
消息面上，公司近期宣布了两项重要进展。首先，已与制药巨头诺和诺德达成新的合作伙伴关系，同时诺和诺德同意撤回此前对Hims & Hers Health提起的诉讼；其次，公司为推进战略转型，已聘请曾在礼来负责公司传播事务长达五年的资深公关人士担任首席传播官。
这些举措被视为公司从销售仿制药转向专注于提供品牌药物战略转型的重要一步，增强了市场对其在快速增长减肥药市场前景的信心。
远程医疗平台Hims & Hers Health Inc.（HIMS）今日夜盘股价大涨5.02%，引起了市场的广泛关注。
消息面上，公司近期宣布了两项重要进展。首先，已与制药巨头诺和诺德达成新的合作伙伴关系，同时诺和诺德同意撤回此前对Hims & Hers Health提起的诉讼；其次，公司为推进战略转型，已聘请曾在礼来负责公司传播事务长达五年的资深公关人士担任首席传播官。
这些举措被视为公司从销售仿制药转向专注于提供品牌药物战略转型的重要一步，增强了市场对其在快速增长减肥药市场前景的信心。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.